Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
U.S. Disinfecting Cap Market – Market Insights
Disinfecting caps are attached to injection ports of needle-free connectors to ensure that needle-free connectors are always clean. These caps protect the needleless connectors from contamination which reduce the risk of hospital acquired infections such as central line blood stream infection (CLABSI).
Central line procedures pose a risk of hospital acquired infections such as central line blood stream infection (CLABSI) and catheter associated urinary tract infection (CAUTI). Central line blood stream infection (CLABSI) is the major infection caused due to the use of central line devices as it accesses a major vein which is close to the heart. In some severe health conditions, it has to be inserted in the vein for weeks or months, which can cause central line blood stream infections. Disinfecting caps are used for the prevention of central line-associated bloodstream infection (CLABSI).
Disinfecting caps are widely used to protect the access points/ports of hemodialysis central venous catheters (HDCVCs). During hemodialysis, the repeated exposure of CVCs to the patients' veins may increase the risk of a catheter-related bloodstream infection (CRBSI) in patients.
The U.S. disinfecting cap market is expected to be valued at US$ 359.3 million in 2019, and is expected to exhibit a CAGR of 10.7% over the forecast period (2019-2027).
Increasing incidence of hospital-acquired infections is expected to propel the market growth over the forecast period
Infections acquired in hospitals and other healthcare settings are considered as the most frequent adverse event affecting millions of patients in hospitals and healthcare settings. According to the Centers for Disease Control and Prevention (CDC) estimation in January 2020, each year, an estimated 30,100 central line-associated bloodstream infections (CLABSI) occur in intensive care units and acute care facilities in the U.S. CLABSI is a serious blood-related infection, which may prolong hospital stays and increase the risk of mortality. The increasing incidence of central line-associated bloodstream infections (CLABSI) and other hospital acquired infections can be controlled and reduced by using disinfecting caps, which is predicted to favour the growth of the U.S. disinfecting cap.
Figure 1. U.S. Disinfecting Cap Market Share (%), by Application, 2027
Source: Coherent Market Insights Analysis (2020)
Increasing product approvals and launches are expected to propel the market growth over the forecast period
Key players in the market are focusing on increasing product approvals and launching innovative disinfecting caps to prevent infections associated with the use of central line IV catheters. Increasing product approval of such new products is expected to drive growth of the U.S. disinfecting cap market over the forecast period. For instance, On February 27, 2017, 3M launched the 3M Curos Stopper Disinfecting Cap which assists clinicians by providing passive disinfection solutions for female luers. The Curos stopper disinfecting cap is the latest offering in the Curos Disinfecting Port Protector family to reduce contamination risk in needleless connectors, male luers, and Tego hemodialysis connectors.
However, availability of antimicrobial coated central venous catheters such as Certofix protect (B.Braun), Cook Spectrum Central Venous Catheter (Cook Medical), and ARROW CVC with ARROWg+ard Technology (Teleflex), which are impregnated with antimicrobial agents are expected to negatively affect demand for disinfecting caps in the near future.
Major players operating in the U.S. disinfecting cap market include ICU Medical, C.R. Bard, Becton, Dickinson and Company, 3M, Merit Medical Systems, and other prominent players.